First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.
[BACKGROUND] Oncolytic virus therapy represents a promising approach in cancer treatment due to its dual mechanisms of direct tumor lysis and immunomodulation.
- 표본수 (n) 28
APA
Ji D, Fu W, et al. (2026). First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.. BMC medicine, 24(1). https://doi.org/10.1186/s12916-026-04695-1
MLA
Ji D, et al.. "First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.." BMC medicine, vol. 24, no. 1, 2026.
PMID
41721376
Abstract
[BACKGROUND] Oncolytic virus therapy represents a promising approach in cancer treatment due to its dual mechanisms of direct tumor lysis and immunomodulation. This study aims to evaluate the safety and efficacy of T3011, a novel oncolytic virus, administered intratumorally in patients with advanced solid tumors including head and neck squamous cell carcinoma (HNSCC).
[METHODS] This study comprised three parts: Part I (single-dose escalation, 2.5 × 10 to 1 × 10 PFU/mL), Part II (multiple-dose escalation, 2.5 × 10 to 1 × 10 PFU/mL), and Part III (expansion phase at the recommended phase 2 dose (RP2D) of 1 × 10 PFU/mL). The primary endpoints for Parts I and II were safety and tolerability, with secondary endpoints including viral biodistribution, shedding, pharmacodynamics, and immunogenicity. In Part III, the primary endpoint was preliminary efficacy assessed according to RECIST v1.1 criteria, with safety as a key secondary endpoint. Exploratory endpoints for Parts II and III included pharmacodynamics and immune-related responses assessed by iRECIST criteria.
[RESULTS] Among the 87 patients treated with T3011 monotherapy in Part III, 74 were evaluable for efficacy. This group achieved an objective response rate (ORR) of 6.8% and a disease control rate (DCR) of 39.2%, with a median duration of response (DOR) of 10.6 months. Within the HNSCC cohort (n = 28), 24 patients were evaluable, showing an ORR of 12.5% and a DCR of 33.3%. Notable immune modulation was observed with increased CD8 T-cell infiltration and conversion of PD-L1-negative to PD-L1-positive tumor posttreatment. No dose-limiting toxicities (DLTs) or severe treatment-related adverse events (TRAEs) were reported.
[CONCLUSIONS] T3011 shows a favorable safety profile, immune-modulating effects, and preliminary efficacy in patients with advanced solid tumors.
[TRIAL REGISTRATION] This study is registered with the China Drug Trial Registry (CTR20192464) and ClinicalTrials.gov (NCT05602792).
[METHODS] This study comprised three parts: Part I (single-dose escalation, 2.5 × 10 to 1 × 10 PFU/mL), Part II (multiple-dose escalation, 2.5 × 10 to 1 × 10 PFU/mL), and Part III (expansion phase at the recommended phase 2 dose (RP2D) of 1 × 10 PFU/mL). The primary endpoints for Parts I and II were safety and tolerability, with secondary endpoints including viral biodistribution, shedding, pharmacodynamics, and immunogenicity. In Part III, the primary endpoint was preliminary efficacy assessed according to RECIST v1.1 criteria, with safety as a key secondary endpoint. Exploratory endpoints for Parts II and III included pharmacodynamics and immune-related responses assessed by iRECIST criteria.
[RESULTS] Among the 87 patients treated with T3011 monotherapy in Part III, 74 were evaluable for efficacy. This group achieved an objective response rate (ORR) of 6.8% and a disease control rate (DCR) of 39.2%, with a median duration of response (DOR) of 10.6 months. Within the HNSCC cohort (n = 28), 24 patients were evaluable, showing an ORR of 12.5% and a DCR of 33.3%. Notable immune modulation was observed with increased CD8 T-cell infiltration and conversion of PD-L1-negative to PD-L1-positive tumor posttreatment. No dose-limiting toxicities (DLTs) or severe treatment-related adverse events (TRAEs) were reported.
[CONCLUSIONS] T3011 shows a favorable safety profile, immune-modulating effects, and preliminary efficacy in patients with advanced solid tumors.
[TRIAL REGISTRATION] This study is registered with the China Drug Trial Registry (CTR20192464) and ClinicalTrials.gov (NCT05602792).
MeSH Terms
Humans; Male; Middle Aged; Female; Aged; Squamous Cell Carcinoma of Head and Neck; Oncolytic Virotherapy; Oncolytic Viruses; Adult; Programmed Cell Death 1 Receptor; Head and Neck Neoplasms; Injections, Intralesional; Neoplasm Recurrence, Local
같은 제1저자의 인용 많은 논문 (4)
- KRAS-Driven Hypertranscription and Metastatic Dissemination in Colorectal Cancer Could be Overcome by Targeting the NMHC IIA/ PLK1 Signaling Axis with a Novel Acridine Derivative.
- Low-level viremia increases the risk of adverse long-term outcomes in entecavir-treated patients with chronic hepatitis B.
- The functional roles of deoxyelephantopin potential target circTNPO3 in regulating pancreatic cancer malignant phenotype and gemcitabine chemoresistance via miR-188-5p/CDCA3/TRAF2-mediated remodeling of NF-κB signaling pathway.
- Role of TRPM2 in brain tumours and potential as a drug target.